# Perspectives of stakeholders on post-trial access arrangements in Ethiopia: a qualitative study

**Authors:** Gudina Terefe Tucho, Cynthia Khamala Wangamati, Diribe Makonene Kumsa, Rosemarie de la Cruz Bernabe

PMC · DOI: 10.1080/11287462.2025.2497599 · Global Bioethics · 2025-05-05

## TL;DR

This study explores how stakeholders in Ethiopia view post-trial access in clinical trials and highlights the need for clear guidelines and collaboration.

## Contribution

The study provides new insights into stakeholder perspectives on post-trial access in Ethiopia, emphasizing the need for legislation and multi-stakeholder collaboration.

## Key findings

- Stakeholders believe both trial participants and communities should benefit from clinical trials.
- Multi-stakeholder collaboration is seen as key to successful post-trial access arrangements.
- Uncertainty about feasibility is due to lack of legislation and fear of sponsor loss.

## Abstract

While there is limited practical experience and guidance on post-trial access (PTA) in clinical trials in low- and middle-income countries, the concept of benefit-sharing is firmly established in international ethical guidelines. Few studies have been conducted in sub-Saharan African on PTA despite its importance in distributive justice. This study aims to explore the stakeholders’ perspectives on PTA and its feasibility in Ethiopia. An exploratory qualitative study using in-depth interviews was conducted with 22 stakeholders involved in clinical trials study and review. Deductive thematic analysis was used to analyze the data. We found that research participants had limited knowledge on PTA. They opined that both trial participants and communities should benefit from clinical trials and multi-stakeholder collaboration was key in PTA planning and arrangements. However, they were uncertain of PTA feasibility in Ethiopia mostly due to a lack of legislation, regulations and guidelines on PTA and fear of losing sponsors because of increased costs resulting from them being obligated to provide PTA. It was recommended that Ethiopia establishes legislation and guidelines to govern PTA. Multi-stakeholder engagement in PTA planning and arrangements is key for meaningful PTA as the responsibility is shouldered by all parties.

## Full-text entities

- **Genes:** PI3 (peptidase inhibitor 3) [NCBI Gene 5266] {aka ESI, SKALP, WAP3, WFDC14, cementoin}
- **Diseases:** COVID-19 (MESH:D000086382), HIV/AIDS (MESH:D015658), NTD (MESH:D058069), PTA (MESH:D000094025), Tuberculosis (MESH:D014376), Malaria (MESH:D008288), FO (MESH:D000092124)
- **Chemicals:** PI4 (-)
- **Species:** Homo sapiens (human, species) [taxon 9606], Human immunodeficiency virus 1 (no rank) [taxon 11676]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12054573/full.md

## References

29 references — full list in the complete paper: https://tomesphere.com/paper/PMC12054573/full.md

---
Source: https://tomesphere.com/paper/PMC12054573